Impact of Smoking on Asthma and the Effect of Leukotriene Receptor Antagonist in asthma with smoking

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-10000998

Enrollment

Unknown

Registered

2010-06-10

Start date

2009-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

Group A:Budesonide 200ug, inhalation, twice daily

salbutamol, inhalation, prn

Montelukast 10mg qn po. for 2 months

Group B:Budesonide 200ug,inhalation, twice daily

salbutamol, inhalation, prn for 1month

Eligibility

Sex/Gender

All

Age

16 Years to 84 Years

Inclusion criteria

Inclusion criteria: 1. the patient has been diagnosed asthma; 2. positive bronchial provocation challenge; 3. normal chest radiograph/CT.

Exclusion criteria

Exclusion criteria: 1. chronic cough and sputum production; 2. impaired diffusing capacity in lung function test.

Design outcomes

Secondary

Measure	Time frame
Blood routine test;IgE level in serum;	—

Primary

Measure	Time frame
lung function;ACT;IL-8 in supernatant of sputum;leucocyte number in sputum;urine LTE4/Cr;ECP in supernatant of sputum;FeNO;TNF-alpha in supernatant of sputum;times of acute exacerbation in last year;urine cotinine;	—

Countries

China

Contacts

Public ContactMeiling Jin

mljin118@yahoo.com.cn+86 13701640522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026